Figure 7.
Prevalence of most common adverse events of any grade (≥20%) and grade ≥3 adverse events (≥3%) over time in patients treated with ibrutinib plus obinutuzumab.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.